Companies › CSPC Mingfule Pharmaceutical (Guangzhou)
1 active drug program in 34 registered trials: 22 Phase 3, 7 Phase 2, 4 Phase 4, 1 Phase 1; Neurology, Cardiovascular; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tenecteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke; ST-segment Elevation Myocardial Infarction (STEMI); Ischemic Stroke; Stroke, Ischemic … | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06814964 | Tenecteplase | Phase 1 | Intraventricular Hemorrhage | Cardiovascular | May 2025 |
| NCT06414499 | Tenecteplase | Phase 3 | Minor Ischemic Stroke | Neurology | Jul 2026 |
| NCT06658197 | Tenecteplase | Phase 3 | Stroke, Ischemic | Neurology | Dec 2026 |
| NCT06904911 | Tenecteplase | Phase 2 | Acute Ischemic Stroke From Large Vessel Occlusion | Neurology | Dec 2026 |
| NCT03998319 | Tenecteplase | Phase 3 | STEMI | Cardiovascular | Dec 2026 |
| NCT06749834 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Dec 2026 |
| NCT06954155 | Tenecteplase | Phase 3 | Stroke | Neurology | Feb 2027 |
| NCT06868511 | Tenecteplase | Phase 3 | Deep Intracerebral Hemorrhage (ICH) | Neurology | Mar 2027 |
| NCT07047014 | Tenecteplase | Phase 3 | Stroke, Ischemic | Neurology | Mar 2027 |
| NCT05199662 | Tenecteplase | Phase 3 | Ischemic Stroke, Acute | Neurology | Jul 2027 |
| NCT05199194 | Tenecteplase | Phase 3 | Stroke, Ischemic | Neurology | Jul 2027 |
| NCT05892510 | Tenecteplase | Phase 2 | Ischemic Stroke, Acute | Neurology | Aug 2027 |
| NCT07201688 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Sep 2027 |
| NCT07357987 | Tenecteplase | Phase 3 | Ischemic Stroke | Neurology | Sep 2027 |
| NCT06987305 | Tenecteplase | Phase 3 | Stroke, Acute Ischemic | Neurology | Oct 2027 |
| NCT06769256 | Tenecteplase | Phase 4 | ST-segment Elevation Myocardial Infarction (STEMI) | Cardiovascular | Dec 2027 |
| NCT07375953 | Tenecteplase | Phase 2 | Ischemic Stroke | Neurology | Dec 2027 |
| NCT07375966 | Tenecteplase | Phase 2 | Ischemic Stroke | Neurology | Dec 2027 |
| NCT07203625 | Tenecteplase | Phase 4 | Acute Ischemic Stroke | Neurology | Dec 2027 |
| NCT06994975 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Mar 2028 |
| NCT07253181 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Mar 2028 |
| NCT05105633 | Tenecteplase | Phase 2 | Basilar Artery Occlusion | Cardiovascular | May 2028 |
| NCT06949228 | Tenecteplase | Phase 2 | Ischemic Stroke | Neurology | May 2028 |
| NCT07092709 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Sep 2028 |
| NCT07606807 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Dec 2028 |
| NCT07475949 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Dec 2028 |
| NCT07302854 | Tenecteplase | Phase 2 | Acute Ischemic Stroke | Neurology | Dec 2028 |
| NCT06878066 | Tenecteplase | Phase 3 | Stroke | Cardiovascular | Dec 2028 |
| NCT06571149 | Tenecteplase | Phase 4 | Ischemic Stroke | Neurology | Jan 2029 |
| NCT07668323 | Tenecteplase | Phase 3 | Medium Vessel Occlusion | Neurology | Jan 2029 |
| NCT07748039 | Tenecteplase | Phase 3 | Acute Ischemic Stroke | Neurology | Mar 2029 |
| NCT06010628 | Tenecteplase | Phase 4 | Stroke, Ischemic | Neurology | Dec 2029 |
| NCT06352632 | Tenecteplase | Phase 3 | Stroke | Neurology | Sep 2034 |
| NCT06352632 | Tenecteplase | Phase 3 | Stroke | Neurology | Sep 2034 |
Shenzhen Ausa Pharmed Eidos Therapeutics, a BridgeBio company Bracco Diagnostics THPharm Ever Neuro Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.